In São Paulo, the Prevent Senior hospital had 96 deaths from coronavirus until March 22, 2020.
Since the hospital adopted a protocol of early treatment with HCQ, AZ and zinc, it has not registered any additional deaths from COVID-19 and had only one patient in the ICU. April 4, 2020
Of
3005 COVID-19 positive patients at the Méditerranée Infection hospitals (APHM/IHU) in France (as of April 4), 1818 patients have been treated with HCQ and AZ. Below are the outcomes:
Dr. Vladimir Zelenko, a board-certified family practitioner in New York,
treated his 700th coronavirus patient with combination therapy of HCQ, AZ and Zinc. Of these patients, 694 recovered with outpatient therapy and, of the 6 requiring hospitalization, only one patient died after, per Dr. Zelenko, not following his treatment protocol. April 3, 2020
Unpublished data from an open-label, multicenter, non-randomized trial in China of 197 patients showed that COVID-19 positive patients treated with chloroquine for 10 days had a higher rate of negative PCR testing by day 10 compared to controls (91.4% vs 57.4%, P < 0.001) and a shorter duration of fever (P = 0.003).
Video and results slide here. March 26, 2020
In a review by the Italian Society for Rheumatology, 65,000 patients on long term treatment with hydroxychloroquine for rheumatoid arthritis and lupus showed only 20 patients infected with COVID-19. This is an infection rate of 0.03%. Of those 20 infected patients, there were no ICU admissions and no deaths. Compared to the testing confirmed infection rate in Italy of 0.33%, this study suggests that prophylactic use of hydroxychloroquine could reduce the rate of infection by 90%.
Sign up with Google
